Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcus Biosciences, Inc.RCUS · Entity 4104 | Director | February 06, 2025 | February 10, 2025 |
| Atara Biotherapeutics, Inc.ATRA · Entity 6828 | Global Head of R&D | May 07, 2019 | May 08, 2019 |
| GILEAD SCIENCES, INC.GILD · Entity 405 | Chief Medical Officer | September 10, 2026 | September 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcus Biosciences, Inc.
Report date February 06, 2025 · Filed February 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
Holding disclosure · report date 2025-02-06 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 0 |
Atara Biotherapeutics, Inc.
Report date May 07, 2019 · Filed May 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 85,678 |
Reported balance
After 2019-05-07 transaction · row 1
1 source rowRow 1 · 2019-05-07 · Tax withholding · Disposed 4,322 · Balance 85,678 F1: Shares withheld to cover tax obligation from settlement of vested restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld to cover tax obligation from settlement of vested restricted stock units.
GILEAD SCIENCES, INC.
Report date September 10, 2026 · Filed September 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,522 |
Ending reported balance
After 2026-09-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-10 · Exercise / conversion · Acquired 533 · Balance 19,785 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Row 2 · 2026-09-10 · Tax withholding · Disposed 263 · Balance 19,522 |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 46,395 |
Reported balance
After 2026-09-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-10 · Exercise / conversion · Disposed 533 · Balance 46,395 F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
F2: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2026 Filed Sep 11, 2026 22:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 533 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001739515-26-000011 · wk-form4_1789165789.xml · derivative · entry 3 Berger Dietmar · CIK 0001739515 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,395 Underlying: Common Stock · 533 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 263 | $144.81 | $38,085.03 |
DisclosureSEC source: 0001739515-26-000011 · wk-form4_1789165789.xml · nonDerivative · entry 2 Berger Dietmar · CIK 0001739515 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,522 Read SEC document |
| September 10, 2026 Filed Sep 11, 2026 22:29 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 533 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001739515-26-000011 · wk-form4_1789165789.xml · nonDerivative · entry 1 Berger Dietmar · CIK 0001739515 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,785 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 22:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 533 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001739515-26-000008 · wk-form4_1781217354.xml · derivative · entry 3 Berger Dietmar · CIK 0001739515 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,928 Underlying: Common Stock · 533 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 22:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 263 | $121.48 | $31,949.24 |
DisclosureSEC source: 0001739515-26-000008 · wk-form4_1781217354.xml · nonDerivative · entry 2 Berger Dietmar · CIK 0001739515 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,252 Read SEC document |
| June 10, 2026 Filed Jun 11, 2026 22:35 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 533 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001739515-26-000008 · wk-form4_1781217354.xml · nonDerivative · entry 1 Berger Dietmar · CIK 0001739515 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,515 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 31,475 | $0.00 Strike: $148.56 | $0.00 |
DisclosureSEC source: 0001739515-26-000006 · wk-form4_1773346941.xml · derivative · entry 5 Berger Dietmar · CIK 0001739515 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,475 Underlying: Common Stock · 31,475 shares Expires 2036-03-10 F3 · derivative.exercise_date: The stock options have a four-year vesting schedule. 25% of the options vest on the first anniversary date of the grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 8,415 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001739515-26-000006 · wk-form4_1773346941.xml · derivative · entry 4 Berger Dietmar · CIK 0001739515 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,461 Underlying: Common Stock · 8,415 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 2,133 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001739515-26-000006 · wk-form4_1773346941.xml · derivative · entry 3 Berger Dietmar · CIK 0001739515 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,046 Underlying: Common Stock · 2,133 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 1,063 | $148.56 | $157,919.28 |
DisclosureSEC source: 0001739515-26-000006 · wk-form4_1773346941.xml · nonDerivative · entry 2 Berger Dietmar · CIK 0001739515 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,982 Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:22 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,133 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001739515-26-000006 · wk-form4_1773346941.xml · nonDerivative · entry 1 Berger Dietmar · CIK 0001739515 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,045 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| February 27, 2026 Filed Mar 2, 2026 21:51 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantCommon Stock | 8,530 | $0.00 | $0.00 |
DisclosureSEC source: 0001739515-26-000004 · wk-form4_1772488286.xml · nonDerivative · entry 1 Berger Dietmar · CIK 0001739515 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,912 F1 · kind: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on March 10, 2025. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation and Talent Committee of the Issuer's Board of Directors. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 22:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionRestricted Stock Unit · Derivative | 16,326 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001739515-26-000002 · wk-form4_1767653790.xml · derivative · entry 3 Berger Dietmar · CIK 0001739515 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,179 Underlying: Common Stock · 16,326 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units vest in approximately three equal installments on the first three anniversaries of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units vest in approximately three equal installments on the first three anniversaries of the date of grant until fully vested. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 22:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Tax withholdingCommon Stock | 6,944 | $121.60 | $844,390.40 |
DisclosureSEC source: 0001739515-26-000002 · wk-form4_1767653790.xml · nonDerivative · entry 2 Berger Dietmar · CIK 0001739515 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,382 Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 22:56 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 16,326 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001739515-26-000002 · wk-form4_1767653790.xml · nonDerivative · entry 1 Berger Dietmar · CIK 0001739515 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,326 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 22:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (Right to Buy) · Derivative | 37,710 | $0.00 Strike: $117.21 | $0.00 |
DisclosureSEC source: 0001127602-25-009263 · form4.xml · derivative · entry 2 Berger Dietmar · CIK 0001739515 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,710 Underlying: Common Stock · 37,710 shares Expires 2035-03-10 F3 · derivative.exercise_date: The options have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| March 10, 2025 Filed Mar 12, 2025 22:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 8,530 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-009263 · form4.xml · derivative · entry 1 Berger Dietmar · CIK 0001739515 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,505 Underlying: Common Stock · 8,530 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. F2 · derivative.expiration_date: The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 23:38 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantRestricted Stock Unit · Derivative | 48,975 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-25-000548 · form4.xml · derivative · entry 1 Berger Dietmar · CIK 0001739515 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,975 Underlying: Common Stock · 48,975 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F1 · price: Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. F2 · derivative.exercise_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on the anniversary of the date of grant until fully vested. F2 · derivative.expiration_date: The restricted stock units have a three year vesting schedule. 33.33% will vest on the anniversary of the date of grant until fully vested. Read SEC document |
| May 07, 2019 Filed May 8, 2019 20:32 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | Tax withholdingCommon Stock | 4,322 | $33.46 | $144,614.12 |
DisclosureSEC source: 0001209191-19-028232 · doc4.xml · nonDerivative · entry 1 Berger Dietmar · CIK 0001739515 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,678 F1 · kind: Shares withheld to cover tax obligation from settlement of vested restricted stock units. Read SEC document |
| March 26, 2019 Filed Mar 27, 2019 21:17 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-021442 · doc4.xml · nonDerivative · entry 1 Berger Dietmar · CIK 0001739515 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 F1 · shares: These restricted stock units vest as to 50% of the shares on March 26, 2020 and 50% of the shares on March 26, 2021, subject to the reporting person's continuous service. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:26 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $38.47 | $0.00 |
DisclosureSEC source: 0001209191-19-008518 · doc4.xml · derivative · entry 2 Berger Dietmar · CIK 0001739515 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-02-05 F2 · derivative.exercise_date: 1/48th of the shares subject to the stock option vest and become exercisable each month following February 6, 2019, subject to the reporting person's continuous service. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:26 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008518 · doc4.xml · nonDerivative · entry 1 Berger Dietmar · CIK 0001739515 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 F1 · shares: These restricted stock units vest in four equal annual installments on each of the first, second, third and fourth anniversaries of the grant date, subject to the reporting person's continuous service. Read SEC document |
| May 07, 2018 Filed May 7, 2018 23:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantEmployee Stock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $42.05 | $0.00 |
DisclosureSEC source: 0001209191-18-028449 · doc4.xml · derivative · entry 2 Berger Dietmar · CIK 0001739515 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2025-05-06 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on May 7, 2019 and the remaining shares vest in equal monthly installments over the following 36 months. Read SEC document |
| May 07, 2018 Filed May 7, 2018 23:02 UTC | Atara Biotherapeutics, Inc. ATRA · Entity 6828 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-028449 · doc4.xml · nonDerivative · entry 1 Berger Dietmar · CIK 0001739515 · Global Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · shares: 25% of the shares subject to restricted stock units vest on May 7, 2019 and the remaining shares vest in equal annual installments over the following 3 years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.